Compare Johnson & Johnson (JNJ) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Johnson & Johnson trades at $251.01 (market cap $598.96B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.54. The key difference: Johnson & Johnson pays a 2.15% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| JNJ | VCIT | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | Fixed Income |
52-Week High | $267.24 | $84.82 |
52-Week Low | $164.36 | $81.45 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $250.61, down 0.96% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $2.90 versus $2.84 expected, and revenue growth of 6.6% year-over-year. The stock shows robust profitability with a net income margin of 21.48% and ROE of 26.42%, supported by consistent dividend payments including the recent $1.34 per share declared for H1-2026.
JNJ presents a favorable investment case with analyst consensus price target of $279.33 implying ~11% upside, though rising debt-to-asset ratio to 24.06% in 2025 and volatile cash flow trends pose risks. The healthcare giant's diversified portfolio and raised full-year guidance underpin long-term stability, but investors should monitor execution amid competitive and regulatory pressures.
VCIT trades at $81.71, down 0.28% on the day, with a bearish technical signal driven by moving averages. The fund provides exposure to intermediate-term corporate bonds, offering a competitive yield and low expense ratio. Recent news highlights its role in fixed-income portfolios, comparing favorably on cost and income potential against peers like iShares alternatives.
Outlook remains cautious near-term due to technical weakness, but the fund's low-cost structure and steady dividends appeal for income-focused investors. Risks include interest rate sensitivity and corporate credit conditions, requiring monitoring of economic indicators for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
